Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Pluri ( (PLUR) ) is now available.
Pluri has announced a merger with another subsidiary under the same parent company, contingent upon the board of directors’ approval. The merger involves a private offering based on the parent company’s share profitability, and the agreement is set to be formalized today. The company plans to issue a report to the SEC and hold a special shareholders’ meeting on February 25, 2025, where the company’s shares will begin trading on the stock exchange.
More about Pluri
Pluri is a biopharmaceutical company that operates as a subsidiary of Alden, focusing on developing pharmaceutical products. The company is involved in merging with another subsidiary under the control of a parent company, aiming to enhance its market position.
YTD Price Performance: 6.70%
Average Trading Volume: 17,971
Technical Sentiment Consensus Rating: Buy
See more insights into PLUR stock on TipRanks’ Stock Analysis page.